Bladder cancer

Critical Reviews in Oncology/Hematology

Volumn 41, Issue 1, 2002, Pages 89-106

  De Braud, Filippo ^a   Maffezzini, Massimo ^b   Vitale, Vito ^c   Bruzzi, Paolo ^c   Gatta, Gemma ^d   Hendry, William F ^e   Sternberg, Cora N ^f  

^a EUROPEAN SCHOOL OF ONCOLOGY   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f Fondazione Centro S Raffaele del Monte Tabor   (Italy)

Author keywords

Bladder cancer; Carcinogens; Urogenital tract

Indexed keywords

ANILINE; ANTINEOPLASTIC AGENT; AROMATIC AMINE; BCG VACCINE; DOCETAXEL; DYE; GEMCITABINE; PACLITAXEL; TAXOID; TOBACCO SMOKE;

BLADDER CANCER; BLADDER MUCOSA; BLADDER MUSCLE; BLADDER SURGERY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CYSTECTOMY; DISEASE COURSE; ENDOSCOPIC SURGERY; HISTOLOGY; HUMAN; LAMINA PROPRIA; METASTASIS; RECURRENCE RISK; REVIEW; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC AGENTS; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 0036142313     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00128-7     Document Type: Review

References (65)

1. Urinary system
2. Cancer prevalence in Italian cancer registry areas: the ITAPREVAL study. ITAPREVAL Working Group
3. Detecting bladder cancer
4. Pathways of development and progression in bladder cancer: new correlations between clinical observations and molecular mechanisms
5. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer
6. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up
7. Flow cytometry and cytology as response indicators to M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin)
8. Expression of a multidrug-resistance gene in human tumors and tissues
9. Invasive bladder cancer treated with neoadjuvant MVAC: the relationship of p53 nuclear overexpression with survival
10. Tumor autocrine motility factors
11. Non transitional cell bladder cancer
12. Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group
13. Superficial bladder cancer: progression and recurrence
14. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party)
15. The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The Memorial Sloan-Kettering Cancer Center experience
16. Carcinoma in situ
17. Follow-up after cystectomy for carcinoma of the bladder
18. The treatment of advanced bladder cancer
19. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses?
20. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder
21. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial
22. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study
23. Intravesical BCG: current results, natural history and implications for urothelial cancer prevention
24. Bladder cancer: improving patient selection and treatment
25. The treated natural history of high risk superficial bladder cancer: 15-year outcome
26. Cancer of the bladder
27. The role of radiation therapy in the management of transitional cell carcinoma of the bladder
28. BCG in perspective: advances in the treatment of superficial bladder cancer
29. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome
30. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group
31. Bladder preservation by combined modality therapy for invasive bladder cancer
32. Nordic prospective trials of radical cystectomy and neoadjuvant chemotherapy. The Nordic Cooperative Bladder Cancer Study Group
33. Surgery for invasive bladder cancer
34. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy
35. Ileal orthotopic bladder substitutes. What we have learned from 12 years' experience with 200 patients
36. Lower urinary tract reconstruction following cystectomy in women using the Kock ileal reservoir with bilateral ureteroileal urethrostomy: initial clinical experience
37. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder
38. Neoadjuvant and adjuvant chemotherapy in advanced disease - what are the effects on survival and prognosis?
39. Randomised intercontinental trial of locoregional therapy with or without neoadjuvant chemotherapy
40. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group
41. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer-Genitourinary Group
42. Radiotherapy and chemotherapy in invasive bladder cancer with potential bladder sparing
43. Selective bladder preservation by combination treatment of invasive bladder cancer
44. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder
45. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder
46. Systemic chemotherapy of muscle-invasive bladder cancer
47. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy
48. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors
49. Interim toxicity analysis of a randomised trial in advanced urothelial tract tumours of high-dose intensity MVAC (HD-MVAC) and recombinant human granulocyte colony stimulating factor (G-CSF) versus classic MVAC chemotherapy (EORTC 30924)
50. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study
51. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer
52. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer
53. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
54. A phase II study of gemcitabine and cisplatin in patients with transitional cell carcinoma (TCC) of the urothelium
55. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group
56. Open bladder surgery
57. Bladder carcinoma. Sequelae of treatment
58. Urethral recurrences following radical cystectomy for invasive transitional cell carcinoma of the bladder
59. Management of ureteral and renal pelvic recurrence after cystectomy